NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $1.29 +0.06 (+4.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.18▼$1.3050-Day Range$1.02▼$1.4052-Week Range$0.53▼$2.35Volume16,306 shsAverage Volume50,631 shsMarket Capitalization$30.86 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get RenovoRx alerts: Email Address RenovoRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside546.7% Upside$8.33 Price TargetShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector812th out of 936 stocksPharmaceutical Preparations Industry378th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRenovoRx has only been the subject of 1 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 24.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNXT. Previous Next 1.8 News and Social Media Coverage News SentimentRenovoRx has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RenovoRx this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about RenovoRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About RenovoRx Stock (NASDAQ:RNXT)RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Read More RNXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNXT Stock News HeadlinesJuly 8, 2024 | globenewswire.comRenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®July 8, 2024 | globenewswire.comRenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®July 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…June 26, 2024 | globenewswire.comUniversity of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical TrialJune 10, 2024 | globenewswire.comRenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and PartnershipsMay 30, 2024 | businesswire.comRenovoRx CEO Issues Update Letter to ShareholdersMay 21, 2024 | finance.yahoo.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryMay 21, 2024 | businesswire.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 14, 2024 | finance.yahoo.comRenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024May 13, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024May 2, 2024 | businesswire.comRenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024April 26, 2024 | finance.yahoo.comRenovoRx Regains Compliance with Nasdaq Stockholders’ Equity RequirementApril 20, 2024 | investing.comRenovoRx meets Nasdaq stockholders equity requirementApril 18, 2024 | fr.investing.comRenovoRx répond aux exigences du Nasdaq en matière de capitaux propresApril 18, 2024 | businesswire.comRenovoRx Regains Compliance with Nasdaq Stockholders' Equity RequirementApril 16, 2024 | businesswire.comRenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingApril 15, 2024 | finance.yahoo.comRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026See More Headlines Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNXT CUSIPN/A CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+546.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,860.14% Return on Assets-203.57% Debt Debt-to-Equity RatioN/A Current Ratio4.26 Quick Ratio4.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-4.60Miscellaneous Outstanding Shares23,952,000Free Float22,251,000Market Cap$30.86 million OptionableNot Optionable Beta1.01 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ramtin Agah M.D. (Age 58)Founder, Chairman of Board & Chief Medical Officer Comp: $332.89kMr. Shaun R. Bagai (Age 47)CEO, Secretary & Director Comp: $589.38kMr. Ronald B. Kocak CPA (Age 67)CGMA, VP, Controller & Principal Accounting Officer Ms. Leesa Gentry (Age 54)Chief Clinical Officer Key CompetitorsCalciMedicaNASDAQ:CALCRockwell MedicalNASDAQ:RMTIAdicet BioNASDAQ:ACETOptiNoseNASDAQ:OPTNI-MabNASDAQ:IMABView All CompetitorsInsidersAngela NelmsBought 1,100 shares on 10/3/2023Total: $1,155.00 ($1.05/share)View All Insider Transactions RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $2.29 at the beginning of the year. Since then, RNXT shares have decreased by 43.7% and is now trading at $1.2885. View the best growth stocks for 2024 here. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) announced its quarterly earnings results on Friday, May, 10th. The company reported ($0.07) EPS for the quarter. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNXT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNXT Stock Alerts